{"id":"NCT02268994","sponsor":"Keryx Biopharmaceuticals","briefTitle":"KRX-0502 (Ferric Citrate) for the Treatment of IDA in Adult Subjects With NDD-CKD","officialTitle":"A Phase 3 Study of KRX-0502 (Ferric Citrate) for the Treatment of Iron Deficiency Anemia (IDA) in Adult Subjects With Non-Dialysis Dependent (NDD) Chronic Kidney Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10","primaryCompletion":"2016-01","completion":"2016-01","firstPosted":"2014-10-20","resultsPosted":"2018-02-22","lastUpdate":"2018-03-22"},"enrollment":234,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Anemia of Chronic Kidney Disease"],"interventions":[{"type":"DRUG","name":"ferric citrate","otherNames":["KRX-0502"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"KRX-0502 (ferric citrate)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"a 24-week phase 3, multi-center clinical trial, comprised of a 16-week, randomized, double-blind, placebo-controlled period (\"Randomized Period\"), followed by an 8-week open-label safety extension period, where all subjects receive KRX-0502 (ferric citrate) (\"Extension Period\").","primaryOutcome":{"measure":"Percentage of Subjects Achieving an Increase in Hemoglobin of â‰¥1.0 g/dL at Any Time Point Between Baseline and the End of the 16-week Randomized Period","timeFrame":"Week 16","effectByArm":[{"arm":"KRX-0502 (Ferric Citrate)","deltaMin":61,"sd":null},{"arm":"Placebo","deltaMin":22,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":36,"countries":["United States"]},"refs":{"pmids":["40576086"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":117},"commonTop":["Diarrhoea","Constipation","Faeces Discoloured","Nausea","Hyperkalaemia"]}}